A Crossover Study Assessing the Pharmacokinetics, Pharmacodynamics, and Safety of Recombinant Human Insulin

Baxter

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: Insulin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00358553

CT 101-002

Details and patient eligibility

About

The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, and safety of recombinant human insulin. The study will consist of 2 phases.

Sex: Male

Ages: 18 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy Male Subjects
• Age between 18 and 40 years of age

Exclusion criteria

• History of Diabetes
• Subjects with clinically significant active disease
• Known allergy to insulin